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Background: MYCT1, previously named MTLC, is a novel candidate tumor suppressor gene. MYCT1 was cloned from
laryngeal squamous cell cancer (LSCC) and has been found to be down-regulated in LSCC; however, the regulatory
details have not been fully elucidated.
Methods: Here, we sought to investigate the methylation status of the CpG islands of MYCT1 and mRNA levels by
bisulfite-specific PCR (BSP) based on sequencing restriction enzyme digestion, reverse transcription and real-time
quantitative polymerase chain reaction (RQ-PCR). The function of specific sites in the proximal promoter of MYCT1
in LSCC was measured by transient transfection, luciferase assays, electrophoretic mobility shift assay (EMSA) and
chromatin immunoprecipitation assay (ChIP).
Results: The results suggested hypermethylation of 12 CpG sites of the promoter in both laryngeal cancer
tissues and the laryngeal cancer line Hep-2 cell. The hypermethylation of the site CGCG (−695 to −692), which
has been identified as the c-Myc binding site, was identified in laryngeal cancer tissues (59/73) compared to
paired mucosa (13/73); in addition, statistical analysis revealed that the methylation status of this site significantly
correlated with cancer cell differentiation(p< 0.01). The mRNA level of MYCT1 increased in Hep-2 cells treated
with 5-aza-C (p< 0.01). The luciferase activity from mutant transfectants pGL3-MYCT1m (−852/+12, mut-695-C>A,
mut-693-C>G) was significantly reduced compared with the wild type pGL3-MYCT1 (−852/+12), while the
luciferase activity from wild transfectants pGL3-MYCT1 (−852/+12) rose after 5-aza treatment in Hep-2 cells. Finally,
EMSA and ChIP confirmed that the methylation of the CGCG (−695 to −692) site prevented c-Myc from binding
of the site and demethylation treatment of the 5′ flanking region of MYCT1 by 5-aza induced the increased
occupation of the core promoter by c-Myc (p< 0.01).
Conclusion: In summary, this study concluded that hypermethylation contributed to the transcriptional
down-regulation of MYCT1 and could inhibit cancer cell differentiation in LSCC. DNA methylation of the CGCG
site (−695 to −692) of MYCT1 altered the promoter activity by interfering with its binding to c-Myc in LSCC.
Epigenetic therapy of reactivating MYCT1 by 5-aza should be further evaluated in clinical trails of LSCC.
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Laryngeal cancer is the second most common respira-
tory system cancer, and the overall incidence of laryngeal
cancer in individuals between 0–44 years old in China
has shown a highly increasing trend in the recent dec-
ades [1,2]. Greater than 90% of laryngeal cancer has
been pathologically identified as laryngeal squamous cell
carcinoma (LSCC) [3]. Currently, the primary treatment
for LSCC is surgery followed by radiotherapy [4]. Total
laryngectomy, the most common type of surgery used in
advanced cases, seriously impairs laryngeal function and
the quality of life of LSCC patients [5]. Therefore, under-
standing the epigenetic pathways involved in the patho-
genesis of LSCC is still urgently needed to improve the
chemotherapeutic and diagnostic molecular biomarkers
to objectively appraise LSCC; in addition, a better under-
standing of these pathways will improve treatment and
increase the survival rate of LSCC patients [6].
MYCT1, which was previously named MTLC (c-Myc
target from laryngeal cancer cells, GenBank access num-
ber AF527367), was cloned by our team in 2003.
MYCT1 is located on 6q25 and has two exons. As a
putative target of c-Myc, MYCT1 is expressed in the
nuclei of human hepatocellular carcinoma cells, while a
wide distribution of MYCT1 has been demonstrated in
various tissues [7]. The closest homolog, mouse MT-MC1
(c-Myc target in myeloid cells-1), can regulate many
c-Myc target genes in myeloid cells, which implies that
like MT-MC1, MYCT1 may participate in the regula-
tion of cell function through the c-Myc signaling network
[8-10]. We previously found that MYCT1 is down-
regulated in gastric cancer [11]. Recently, Fu et al. in our
group found that MYCT1 is transcribed at a low level in
LSCC. These authors also confirmed that the transcrip-
tional start site of MYCT1 is located 140 bp upstream
of the ATG start codon using 5' rapid amplification of
cDNA ends (RACE)(GenBank access number GU997693.1)
and that c-Myc can regulate the promoter activity of
MYCT1 by specifically binding to the E-box elements
within the −886 to −655 bp region [12].
c-Myc is a transcription factor that forms heterodi-
mers with the protein Max and binds gene promoters by
recognizing the DNA sequence CACGTG, which is called
a canonical E-box [13]. c-Myc can also bind several other
non-canonical E-box motifs, such as CATGTG, CATGCG,
CACGCG, CACGAG, CGCGAG and CAACGTG [14-16].
Understanding the regulation of the expression of c-Myc
target genes is an important step for understanding
their biological functions in both physiological and
pathological contexts [17]. Several studies have demon-
strated that methylation of the CpG dinucleotide within
the E-box can prevent the access of c-Myc to target
gene promoters in vivo [18,19]. This idea has been fur-
ther reinforced by a study that has shown that c-Mycdoes not bind to EGFR in HL-60 cells due to methyla-
tion of the E-box sites, whereas 5-aza-2′-deoxycytidine
(5-aza), a demethylating agent that blocks cellular
DNA methyltransferase activity, can restore the binding
of c-Myc to the E-box and increase gene transcrip-
tion [20]. Based on these premises, a causal link exists
between methylation of the E-box and c-Myc binding
and transcription.
We speculate that MYCT1 might act as a tumor sup-
pressor gene (TSG) in LSCC carcinogenesis and metas-
tasis. The mechanism of abnormal expression of TSGs
in the process of malignant transformation primarily
involves point mutations, loss of heterozygosity, and
epigenetic modifications (such as hypermethylation)
[21]. Specifically, aberrant methylation of CpG islands in
gene-specific promoter regions can affect transcriptional
function and has been found to be related to human dis-
eases [22]. In this study, we sought to investigate the
methylation status of CpG islands, mRNA levels and the
function of specific promoter sites of MYCT1 in LSCC.
Materials and methods
Cell culture
The human laryngeal carcinoma cell line Hep-2 was
obtained from the Cell Biology Institute of Shanghai,
Chinese Academy of Science. The cells were grown in
RPMI-1640 with 10% FBS, penicillin (100 U/ml) and
streptomycin (100 μg/ml) at 37 °C in a 5% CO2 humidi-
fied atmosphere.
Samples and tissue DNA extraction
Seventy-three patients who were diagnosed with resect-
able LSCC tumors at the ENT Department of the 463
Hospital of PLA between 2002 and 2005 were enrolled
in the study. The LSCC tissues were pathologically con-
firmed according to the UICC classification (TNM 2002).
Patients who had undergone radiotherapy or chemother-
apy prior to surgery were excluded from the study. All
of the patients provided written informed consent, and
approval for the study was received from the Ethics
Committee of China Medical University. All specimens,
including cancerous and paired adjacent normal laryngeal
tissues, were obtained fresh during the surgery and stored
at −80 °C. Genomic DNA from the LSCC tissues and
Hep-2 cells was isolated with DNAzol reagent (Invitrogen
Life Technologies, San Diego, CA). Purified DNA was
concentrated by ethanol precipitation. The DNA concen-
tration was determined using a spectrophotometer.
Bisulfite modification and bisulfite-specific PCR (BSP)
Genomic DNA from Hep-2 cells and 10 LSCC samples
was randomly selected for methylation status screening.
Approximately 1 μg of genomic DNA was bisulfite-
modified using the EZ DNA Methylation-Gold KitTM
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facturer's recommendations. Based on the functional
promoter sequence of the MYCT1 gene, the primers (F:
5'-TTAAATAGAGAAATAGATATGTTAAGAATA-3'; R:
5'-TATACAAAATTAAAAAATAAACCAC-3') used in
bisulfite-specific PCR (BSP) detection were designed
using MethPrimer (http://www.urogene.org/methprimer/
index.html), and the amplified fragment was 449 bp. The
PCR reaction was performed in a 25 μl reaction system,
starting with denaturation at 94 °C for 4 min, then 30
cycles of denaturation at 94 °C for 30 sec, annealing at
53 °C for 30 sec, extension at 72 °C for 45 sec, followed by
an extra extension at 72 °C for 5 min. The BSP products
(200 ng) were then cloned into a T-vector (TaKaRa, Japan),
and JM109 E. coli competent cells (TaKaRa, Japan) were
used for transformation according to the manufacturer’s in-
struction. The sequence of the BSP product was obtained
using the ABI model 3730 sequencer. According to the
previous study, full methylation at a particular CpG island
was defined as follows: >60% of the average bisulfite se-
quencing signal was “C,” whereas partial methylation was
40% to 60%. “Methylation-positive” was defined as at least
6 of the 12 CpGs within the BSP product showing full or
partial methylation [23]. We then detected the methylation
status of the CGCG site within the non-canonical E-box
motif binding to c-Myc, CACGCG, in other LSCC
tissues using BSP-based RFLP by cutting the AccII site.
Briefly, 8.5 μl of BSP product digestion was initiated
by adding 1 μl of 10X Buffer and 0.5 μl of 10 U/μl
AccII(TaKaRa, Japan) for 6 to 7 hours in a 37 °C water bath,
5 μl of the product was analyzed on 2.5% agarose gels and
the gel image was visualized under a GDS8000 (UVP, USA).
Reverse transcription and real-time quantitative
polymerase chain reaction (RQ-PCR)
After culture in a 6-well plate for 24 h, Hep-2 cells were
treated with 4 μM 5-aza (Sigma Chemical Co.) for 3 days
as previously described [23]. BSP was used again to
detect wether Hep-2 cells had been demethylated or not.
Total RNA was isolated from Hep-2 cells and Hep-2
cells treated with 5-aza using Trizol reagent (Invitrogen,
USA) following the protocol. cDNA was synthesized by
reverse transcription using an AMV RNA PCR kit
(TaKaRa, Japan). The MYCT1 primers for RQ-PCR
were F: 5'- AGGGAGTCCATGGCCAGAAA -3' and R:
5'- ATGAACACAGCCCAAATAAATCCTC -3', which
amplified a 105 bp product. GAPDH served as an internal
control, which primer sequences were 5'-TGCACCAC-
CAACTGCTTAG -3' and 5'- GACGCAGGGATGATG-
TTC -3' and were expected to produce a 175 bp DNA
fragment. RQ-PCR was carried out on a real-time quanti-
tative PCR instrument (ABI, USA) using a TaKaRa SYBRW
Premix Ex Taq™ kit (TaKaRa, Japan). The 20-μl reaction
system comprised 400 nM primers, 50 ng cDNA and10 μl SYBR Premix Ex Taq™. The cycling was designed as
95 °C for 30 s, 95 °C for 5 s, and 60 °C for 34 s for 50
cycles. Each sample was measured in 3 separate tubes, and
each experiment was run in triplicate. Results of real-time
PCR were processed using a ΔΔCt method [24]. cDNA
from untreated Hep-2 cells was used as calibrator sample.
Plasmid construction and site-directed mutagenesis
We obtained a novel transcript variation of MYCT1
using 5' RACE, named c-Myc target 1 transcript variant
1(GenBank access number GU997693.1), which indi-
cated the transcript start site of MYCT1 and its vari-
ation. Three 5' deletion constructs of p852 (−852/+12),
p799 (−799/+12), and p667 (−667/+12) of the MYCT1
promoter region were generated by our group, and the
results from dual luciferase assays displayed that P852
(−852/+12) acted as the proximal promoter [12]. Based
on the wild-type construct of p852, the P852 mutant
was created to replace the E-box B core sequence
"CACGCG" with "CAAGGG" (named P852-mutB) using
the Gene Tailor site-directed mutagenesis system (Invi-
trogen, USA) according to the manufacturer's instruc-
tions. The primers Fp (forward primer containing site
SacI, 5'-TTTGAGCTCGTGGCCGAGCGCAGT-3'), Rp
(reverse primer containing site HindIII, 5'-TTTAAGCT-
TGTTATTAGCCATAATATCCACAAGA-3'), fm (mutated
forward primer, 5'-GTGTGGTGGCAAGGGCCTGTAAT-
CCC-3') and rm (mutated reverse primer, 5'-GGGATTA-
CAGGCCCTTGCCACCACAC-3') were used in site-directed
mutagenesis. The pMDTM-T Vector (TaKaRa, Japan) was
used for TA cloning and JM109 E. coli competent cells
(TaKaRa, Japan) were used for transformation. Colonies
were selected and rechecked by electrophoresis. The
authenticity of all constructs was confirmed by DNA
sequencing on an ABI 3730xl 96-capillary DNA analyzer
(ABI, US).
Transient transfection and luciferase assays
All of the cells used for the subsequent experiments
were in log phase. Hep-2 cells were cultured in 24-well
plates at a density of 1 × 105 per well overnight in RPMI-
1640 without FBS and antibiotics. P852, P852-mutB or
the empty construct of the luciferase reporter gene
(0.8 μg) and 16 ng of the internal control plasmid pRL-
TK were co-transfected into Hep-2 using Lipofecta-
mine™ 2000 (Invitrogen, USA). The relative luciferase
activity was normalized to the TK activity value. At 6 h
after transfection, RPMI-1640 with FBS and antibiotics
was added to the cells. The cells were harvested at 48 h
after transfection, and the lysates were analyzed for luci-
ferase activity using the Dual Luciferase Reporter assay
(Promega) in a GloMax™ Microplate Luminometer (Pro-
mega). Hep-2 cells pre-treated with 5-aza (4 μM, 3 days)
were used for P852 to be transfected. The results were
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triplicates out of five replicates from which the largest
and the smallest values were excluded from the analysis
are represented as the mean± SD.EMSA (electrophoretic mobility shift assay)
Two sets of complementary oligonucleotides, F: 5’-
CGGGTGTGGTGGCACGCGCCTGTAATCCCA -3’ and
R: 5’-TGGGATTACAGGCGCGTGCCACCACACCCG-3’
including the core sequence of CACGCG(−697 to −692),
were labeled by Biotin 3' End Labeling Kit (Pierce, USA).
EMSA used the Lightshift Chemiluminescent EMSA
kit (Pierce, USA) according to the protocols. Nuclear
extracts were prepared from Hep-2 cells using a nuclear
extract kit (Active Motif, USA) as described in the
instructions. The methylated probe was obtained by
incubating 20 μg of the oligonucleotide with 80 units of
M.SssI CpG methylase for two hours at 37 °C in vitro.
Then, the mixture was heated at 65 °C for 20 min
to inactivate the methylase, purified by polyacrylamide
gel electrophoresis, and concentrated with Centricon 3
microconcentrators. The two types of probes (1 ng) were
incubated with nuclear extracts (6 μg) in protein-DNAFigure 1 Detection of promoter methylation of MYCT1 in LSCC and H
sites and the AccII restriction site in the MYCT1 gene. Arabic numerals 1 to
B. Statistical result of DNA methylation in 10 LSCC paired samples and Hep
image of paired LSCC samples by BSP-based RFLP.binding buffer (2 μl of 10X binding buffer, 1 μl of 50%
Glycerol, 1 μl of MgCl2, 1 μl of poly(dI–dC), and 1 μl of
1% NP-40) on ice for 20 min. Competition reactions
were pre-performed with a 40/100-fold molar excess of
unlabeled, methylated double-stranded competitor DNA.
For the supershift reaction, 1 μg of each anti-c-Myc anti-
body (N-262X, Santa Cruz) was preincubated with the
nuclear extracts in the absence of poly (dIdC) for
20 min at 4 °C. Subsequently, poly (dIdC) was added
and incubated for 5 min, followed by the addition of
labeled probe for an additional 20 min. The DNA-
protein complexes were separated by electrophoresis
on a 6% native polyacrylamide gel for 1.5 to 2.5 h at
4 °C and 100 V, and the complexes were visualized
by autoradiography.Chromatin immunoprecipitation assay (ChIP)
ChIP assay were performed as previously described [12].
Hep-2 cells were treated with 5-aza in accordance with
RQ-PCR. Cells were fixed by the addition of 1% formal-
dehyde in growth medium for 10 min at 37 °C. After
washed with ice-cold PBS, cells were lysed with lysis buf-
fer containing protease inhibitors and chromatin fromep-2 cells. A. Schematic representation of the location of the CpG
12 represent the number of CpG dinucleotides in the region.
-2 cells by BSP-based sequencing. C. Representative electrophoresis










Cancer tissue 73 59 14 P< 0.01
Paired normal tissue 73 13 60
Age at surgery
<60 35 28 7 0.864
>60 38 31 7
Gender
Male 58 47 11 0.928
Female 15 12 3
Histological classification
Poorly differentiated 49 46 3 P< 0.01
Well differentiated 24 13 11
T classification
T1 13 10 3 0.980
T2 26 21 5
T3 28 23 5
T4 6 5 1
Lymph node metastasis
Negative 55 44 11 0.755
Positive 18 15 3
Distant metastasis
Negative 69 56 13 0.761
Positive 4 3 1
Clinical stage
I 13 9 4 0.533
II 22 17 5
III 30 26 4
IV 8 7 1
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was saved as input DNA. The rest was incubated with
anti-c-Myc antibody (N-262X, Santa Cruz), and immu-
noprecipitated by protein A/G plus-agarose (Santa Cruz,
USA) which was eluted and extracted with phenol-
chloroform, whose concentrations were measured with a
spectrophotometer. The input and immunoprecipitated
DNA were used as templates for Real Time PCR per-
formed with MYCT1 core promoter-specific
primer amplifying the second c-Myc binding regions
(c-Myc B, F:5'-GAGGTCAGGCCTAGTTCATG-3', and
R:5'-CTTAGT CTCGCTCTGTCGC-3') in accordance
with RQ-PCR except the difference of 40 cycles. The
percentage of MYCT1 promoter that was bound with
c-Myc B was calculated based on the differences between
Ct values for input and DNA samples immunopre-
cipitated from Hep-2 cells treated or untreated with
5-zaz [25].
Statistical analysis
All statistical analyses were performed using the SPSS
13.0 software. The chi-squared test was utilized to analyze
the relationship between methylation and clinicopatholo-
gical characteristics. The comparisons mRAN level and
percentage of MYCT1 promoter occupation were carried
out using one-way analysis of variance (ANOVA) and the
Students-Newman-Keuls (SNK) method were employed
for group comparison. P values of less than 0.05 were con-
sidered to be statistically significant.
Results
Methylation status of the MYCT1 promoter region
Twelve CpG sites are illustrated in the sequence of the
PCR product (Figure 1A). BSP-based sequencing showed
that 11 of the 12 CpG sites in the MYCT1 gene pro-
moter displayed full methylation except site 12 in Hep-2
cells and LSCC, which indicated that the MYCT1 pro-
moter was methylation-positive (Figure 1B). Both BSP-
based sequencing and RFLP results (Figure 1C) at the
site CGCG (−695 to −692) revealed that 46 of 73 (63%)
cases of LSCC showed methylation in cancer tissues and
no methylation in paired normal tissue, 13 cases showed
methylation in both cancer and paired normal tissues,
and 14 cases showed no methylation in either cancer or
paired normal tissues. These data indicated that a sig-
nificant difference in MYCT1 promoter methylation sta-
tus exists between cancer and paired normal tissues
(Table 1). Tumors classified as undifferentiated or poorly
differentiated compared with those classified as well dif-
ferentiated showed significantly higher methylation. The
MYCT1 hypermethylation in LSCC was not significantly
associated with age, gender, TNM staging, lymph node
metastasis, distant metastasis or clinical stage of the
patients (Table1).Effects of treatment with epigenetic-modifying agents
on MYCT1 mRNA expression
To investigate the possible epigenetic regulation of
MYCT1 expression, RQ-PCR analysis was performed
in Hep-2 cells that did or did not be treated with a
DNA demethylating agent, 5-aza. BSP-based sequencing
revealed that the MYCT1 gene promoter was demethy-
lated in Hep-2 cells by the treatment of 5-aza (Figure 2A).
Following 5-aza treatment of Hep-2 cells, MYCT1
mRNA expression increased, which showed statistically
significant differences among the two groups (p< 0.01)
(Figure 2B). This result suggested that DNA methylation
modification down-regulated MYCT1 gene expression.
Figure 2 Effect of 5-zaz on MYCT1 expression in Hep-2 cells. A. BSP-based sequencing result of all of 12 CpG sites methlated or
demethylated of in Hep-2 cells of the absence or presence of 5-aza. B. MYCT1 mRNA levels in Hep-2 cells. +5-zaz indicates Hep-2 ells were
treated with 5-zaz; MYCT1 mRNA levels were significantly different.** p< 0.01.
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promotion/enhancement
The mutated sites of P852-mutB are illustrated in
Figure 3A. The promoter region between -852 bp and
-667 bp was basal for the transcriptional activity, in
which the putative core promoter sequences (−730 bp
to -681 bp) owned only one DNA motif of regulatory
elements, a noncanonical E-box “CACGCG” [7,12].
To determine whether the CGCG site (−695 to −692)
affected the promoter activity of MYCT1, we created a
plasmid containing mutations in the CGCG site (−695 to
−692), named P852-mutB, based on the wild-type P852
(−852 to +12). The results from a transient transfec-
tion assay showed that the P852 construct expressed a
high level of luciferase activity in Hep-2 cells treated with
5-aza, indicating that some important element in the
construct up-regulates MYCT1 expression. The lucifer-
ase activities in P852-mutB transfectants were signifi-
cantly reduced compared with wild-type P852, whichsuggests that this site plays an important role in regulat-
ing MYCT1 expression (Figure 3B).
Methylation interferes with the binding between the
MYCT1 promoter and c-myc
EMSA confirmed the specific binding by c-Myc antibody
abrogating the band gel shift and the specific shift band
was faint when the biotin-labeled probe methylated
using M.SssI methylase mixed with nuclear proteins
from Hep2 cells (Lane 2, 5 in Figure 4A). In the compe-
tition reaction, the specific band was not effectively
competed when an excess amount of free probes methy-
lated were added before the binding of nuclear proteins
(Lane3,4 in Figure 4A). The effect of promoter methyla-
tion on the interaction between c-Myc and MYCT1 core
promoter was further confirmed by ChIP assay. Using
the primer to amplify c-Myc B binding regions of
MYCT1 promoter, we observed different DNA levels
based on the precipitate by c-Myc antibody from Hep2
Figure 3 Effect of mutation and methylation of site CGCG
(−695~-692) on MYCT1 promoter activity in Hep-2 cells. A.
Schematic representation of the plasmid constructs P852-mutB
created by site-directed mutagenesis. The arrows indicate the
primers used for constructing the mutant construct. B. Luciferase
activities in Hep-2 cells of the presence or absence of 5-aza
transfected with wild-type and mutant vectors of MYCT1.
Figure 4 Effect of methylation of site CGCG (−695~-692) on
MYCT1 promoter banding to c-Myc in Hep-2 cells. A. Binding
ability of site CGCG (−695~-692) to c-Myc. End-labeled M.SssI-treated
methylated and unmethylated MYCT1 promoter region probes
containing CGCG (−695~-692) were mixed with nuclear proteins
from Hep2 cells and separated on a 6% polyacrylamide gel. Lane 1,
end-labeled M.SssI-treated methylated free probe; Lane 2,
end-labeled M.SssI-treated methylated probe mixed with nuclear
proteins; Lane 3,4, the unlabeled M.SssI-treated methylated wild-type
competitor DNA was mixed with the nuclear proteins before adding
end-labeled probe; Lane 5, c-Myc antibody was mixed with the
nuclear proteins before adding end-labeled probe; B. Binding of
E-box B to c-Myc in vivo detected by ChIP. The percentage of the
MYCT1 promoter occupied by c-Myc was significantly different in
Hep-2 cells of present or absent 5-zaz..** p< 0.01.
Yang et al. BMC Cancer 2012, 12:219 Page 7 of 9
http://www.biomedcentral.com/1471-2407/12/219cells and Hep2 cells of 5-aza treatment (Figure 4B). The
quantities of DNA precipitated by c-Myc antibody from
the treated Hep2 cells increased significantly (p< 0.01).
These data suggest that the methylation in the core
sequence including the CGCG site (−695 to −692) inter-
feres with the specific binding of c-Myc.
Discussion
Multiple genetic and epigenetic alterations in tumor sup-
pressor genes and oncogenes are important in carcino-
genesis [26-28]. Therefore, identifying the corresponding
genes and exploring the regulatory mechanisms involved
in tumor progression have become critical issues. DNA
methylation is one of the main mechanisms of epigenet-
ics. Methylation in gene promoter regions has been well
established to contribute to the inactivation of tumor sup-
pressors [29-31].
Our previous study revealed that low MYCT1 expres-
sion is found in LSCC and that MYCT1 can inhibit cell
growth and promote cell apoptosis, which suggests that
MYCT1 may be a candidate TSG [11]. Methylation of
CpG islands has been expected in the MYCT1 promoter
region. The present study focused on the epigenetic
alterations leading to transcriptional down-regulation of
MYCT1, thereby opening a new avenue to understand
the molecular pathways in laryngeal cancer and to
develop potential therapeutics against laryngeal cancer.
In this study, 12 potential methylated sites in the MYCT1
promoter region were predicted in silico, and hypermethy-
lation was observed in 10 LSCC tumor samples and the
Hep2 cancer cells by BSP-based sequencing. Among these
methylated sites, the sequence CGCG (−695 to −692) is
localized in a non-canonical E-box motif, CACGCG, which
specifically binds to the transcription factor c-Myc [12].
We asked whether methylation of the potential c-Mycbinding site plays a role in the regulation of MYCT1. We
further explored the methylation status of CGCG (−695
to −692) using BSP-based RFLP in the subsequent 63
tumor samples. In total, 80.8% of the tumor samples
showed methylation at this site compared to 17.8% in
paired mucosa, which displayed a significant difference.
We observed that methylation of the CGCG site (−695
to −692) significantly correlated with cancer cell differ-
entiation but did not correlate with age, gender and
TNM staging, suggesting that MYCT1 methylation could
inhibit cancer cell differentiation. In our group, Fu et al.
found that the average transcription levels of MYCT1/








Cancer tissue + 59 0.31 ± 0.09 18.620 P< 0.01
- 14 0.88 ± 0.15
Paired tissue + 13 0.25 ± 0.11 14.289 P< 0.01
- 60 0.96 ± 0.17
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cancer tissue and paired normal tissue, respectively [12].
We then analyzed the relationship between the methyla-
tion status of site CGCG (−695~-692) and the transcrip-
tion levels of MYCT1. An inverse correlation between
the methylation status of this site and the MYCT1
mRNA level was pronounced and significant in either
LSCC tissues or paired tissue, which implies that pro-
moter methylation inhibits the transcription of MYCT1
(Table 2).
To confirm that the aberrant methylation of MYCT1
induced transcriptional down-regulation, we compared its
mRNA levels in laryngeal carcinoma Hep2 cells to Hep2
cells treated with the inhibitor of the methylase enzyme
5-aza. We found the MYCT1 mRNA levels of MYCT1
were markedly raised (p< 0.01) after the treatment, sug-
gesting that the gene MYCT1 was suppressed by epigen-
etic modification. The mechanism were found in certain
tumor suppression genes of cancer cell lines [32,33].
To explore how and why methylation of the CGCG
site (−695 to −692) leads to low transcription of MYCT1,
we constructed the wild-type and mutant-type expres-
sing vectors P852 (−852/+12) and P852-mutB. The
results from luciferase assays revealed that the promoter
sequence including the non-canonical E-box motif
CACGCG (−697 to −692) can have promoter activity
and that the point mutation of cytosine at −695 and
−693 impaired the activity of luciferase, suggesting that
aberrations, including methylation, on this site can affect
the promoter activity of MYCT1. Interestingly, with the
action of 5-aza, P852 owned the higher promoter activ-
ity. In further investigation, a CGCG-containing probe
was used in EMSA to identify its binding to c-Myc. The
result confirmed that the non-canonical E-box motif
CACGCG (−697 to −692) could bind to the nuclear
extracts, the specific binding band lessened significantly
because the probe was methylated, while normal labeled
probes could not be competed off by the unlabeled
methylated wild-type probe. In addition, we observed
DNA demethylation was associated with a rising occu-
pancy percentage of the promoter by c-Myc in ChIP
assay. These data suggest that methylation around the
CGCG (−695 to −692) in the MYCT1 promoter might
interfere with the binding of c-Myc to this motif.
According to a previous report, c-Myc controls themethylation status of the core promoter of target genes
through a pathway in which DNA methyltransferase 3A
is recruited depending on the cellular context [33]. In
addition, the cooperation of c-Myc and other proteins
participates in the stable methylation-dependent repres-
sion of downstream genes [34]. Consistent with our study,
c-Myc could mediate transcriptional silencing through
DNA methylation in cell differentiation in cancer [35,36].
5-aza was used to select genes for early detection and
prognostic biomarkers of head and neck squamous cell
carcinoma (HNSCC) [37]. Recently, 5-aza combined
with other therapeutics including irradiation and chemo-
therapy has been considered and tried in the treatment
of LSCC [38,39].
Conclusions
This report is the first to describe transcriptional down-
regulation of the MYCT1 gene through epigenetic path-
ways in malignant tumors. We conclude that MYCT1 is
down-regulated by promoter hypermethylation. Our
data further indicate that the transcription factor c-Myc
participates in the regulation of MYCT1 transcription
and that DNA methylation interferes with the binding
of c-Myc to the MYCT1 promoter region. This result
provides a clue for selection of LSCC patients in 5-aza-
mediated treatment, but how to solve it is also a prob-
lem in further study.
Competing interests
The authors declare that they have no competing interest.
Authors’ contribution
MY performed experiments and WL drafted the manuscript. Y-Y L, SF, G-B Q,
K-L S and W-N F participated in the design of the study and statistics of
data. All authors have read and approved the final manuscript.
Acknowledgements
This work was supported by the National Natural Science Foundation of
China (81102057 and 81172577) and the Natural Science Foundation of
Liaoning Province (20092110).
Author details
1Department of Medical Genetics, China Medical University, Shenyang
110001, P.R. China. 2Shenyang Police-dog Technology School of Ministry of
Public Security, Shenyang 110034, P.R. China. 3ENT Department, the First
Affiliated Hospital of China Medical University, Shenyang 110001, P.R. China.
4Department of Laboratory Medicine, No. 202 Hospital of PLA, Shenyang
110003, P.R. China.
Received: 1 March 2012 Accepted: 6 June 2012
Published: 6 June 2012
Yang et al. BMC Cancer 2012, 12:219 Page 9 of 9
http://www.biomedcentral.com/1471-2407/12/219References
1. Cattaruzza MS, Maisonneuve P, Boyle P: Epidemiology of laryngeal cancer.
Eur J Cancer B Oral Oncol 1996, 32B:293–305.
2. Chen K, Song F, He M, et al: Trends in head and neck cancer incidence in
Tianjin, China, between 1981 and 2002. Head Neck 2009, 31:175–182.
3. Morshed K, Polz-Dacewicz M, Szymanski M, et al: Short-fragment PCR assay
for highly sensitive broad-spectrum detection of human
papillomaviruses in laryngeal squamous cell carcinoma and normal
mucosa: clinico-pathological evaluation. Eur Arch Otorhinolaryngol 2008,
265(Suppl 1):S89–S96.
4. Ma XJ, Pan XL, Lv ZH, et al: Therapeutic influence on circulating and
monocyte-derived dendritic cells in laryngeal squamous cell carcinoma
patients. Acta Otolaryngol 2009, 129:84–91.
5. Kada S, Hirano S, Tateya I, et al: Ten years single institutional experience
of treatment for advanced laryngeal cancer in Kyoto University. Acta
Otolaryngol Suppl 2010, (563):68–73.
6. Marioni G, Marchese-Ragona R, Cartei G, et al: Current opinion in diagnosis
and treatment of laryngeal carcinoma. Cancer Treat Rev 2006, 32:504–515.
7. Qiu G, Xu Z, Huang D, et al: Cloning and characterization of MTLC, a
novel gene in 6q25. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003, 20:94–97.
8. Rogulski KR, Cohen DE, Corcoran DL, et al: Deregulation of common genes
by c-Myc and its direct target, MT-MC1. Proc Natl Acad Sci USA 2005,
102:18968–18973.
9. Reymann S, Borlak J: Transcription profiling of lung adenocarcinomas of
c-myc-transgenic mice: identification of the c-myc regulatory gene
network. BMC Syst Biol 2008, 2:46.
10. Li Y, Lu J, Prochownik EV: c-Myc-mediated genomic instability proceeds
via a megakaryocytic endomitosis pathway involving Gp1balpha. Proc
Natl Acad Sci USA 2007, 104:3490–3495.
11. Qiu GB, Gong LG, Hao DM, et al: Expression of MTLC gene in gastric
carcinoma. World J Gastroenterol 2003, 9:2160–2163.
12. Fu S, Guo Y, Chen H, et al: MYCT1-TV, A Novel MYCT1 Transcript, Is
Regulated by c-Myc and May Participate in Laryngeal Carcinogenesis.
PLoS One 2011, 6:e25648.
13. Dang CV, O'Donnell KA, Zeller KI, et al: The c-Myc target gene network.
Semin Cancer Biol 2006, 16:253–264.
14. Kim J, Lee JH, Iyer VR: Global identification of Myc target genes reveals
its direct role in mitochondrial biogenesis and its E-box usage in vivo.
PLoS One 2008, 3:e1798.
15. Kuznetsov VA, Singh O, Jenjaroenpun P: Statistics of protein-DNA binding
and the total number of binding sites for a transcription factor in the
mammalian genome. BMC Genomics 2010, 11(Suppl 1):S12.
16. Haggerty TJ, Zeller KI, Osthus RC, et al: A strategy for identifying
transcription factor binding sites reveals two classes of genomic c-Myc
target sites. Proc Natl Acad Sci USA 2003, 100:5313–5318.
17. Blackwood EM, Eisenman RN: Max: a helix-loop-helix zipper protein that
forms a sequence-specific DNA-binding complex with Myc. Science 1991,
251:1211–1217.
18. Si J, Yu X, Zhang Y, DeWille JW: Myc interacts with Max and Miz1 to
repress C/EBPdelta promoter activity and gene expression. Mol Cancer
2010, 9:92.
19. Chen PY, Chang WS, Lai YK, et al: c-Myc regulates the coordinated
transcription of brain disease-related PDCD10-SERPINI1 bidirectional
gene pair. Mol Cell Neurosci 2009, 42:23–32.
20. Perini G, Diolaiti D, Porro A, et al: In vivo transcriptional regulation of
N-Myc target genes is controlled by E-box methylation. Proc Natl Acad
Sci USA 2005, 102:12117–12122.
21. Sharp TV, Al-Attar A, Foxler DE, et al: The chromosome 3p21.3-encoded
gene, LIMD1, is a critical tumor suppressor involved in human lung
cancer development. Proc Natl Acad Sci USA 2008, 105:19932–19937.
22. Furuta T, Shuto T, Shimasaki S, et al: DNA demethylation-dependent
enhancement of toll-like receptor-2 gene expression in cystic fibrosis
epithelial cells involves SP1-activated transcription. BMC Mol Biol 2008,
9:39.
23. Wang J, Chen H, Fu S, et al: The involvement of CHD5 hypermethylation
in laryngeal squamous cell carcinoma. Oral Oncol 2011, 47:601–608.
24. Oliveira MS, Skinner F, Arshadmansab MF, et al: Altered expression and
function of small-conductance (SK) Ca(2+)-activated K+channels in
pilocarpine-treated epileptic rats. Brain Res 2010, 1348:187–199.
25. Rawłuszko AA, Horbacka K, Krokowicz P, et al: Decreased expression of
17β-hydroxysteroid dehydrogenase type 1 is associated with DNAhypermethylation in colorectal cancer located in the proximal colon.
BMC Cancer 2011, 11:522.
26. Mullighan CG, Zhang J, Kasper LH, et al: CREBBP mutations in relapsed
acute lymphoblastic leukaemia. Nature 2011, 471:235–239.
27. Lahousse SA, Hoenerhoff M, Collins J, et al: Gene expression and mutation
assessment provide clues of genetic and epigenetic mechanisms in liver
tumors of oxazepam-exposed mice. Vet Pathol 2011, 48:875–884.
28. Arai E, Kanai Y: Genetic and epigenetic alterations during renal
carcinogenesis. Int J Clin Exp Pathol 2010, 4:58–73.
29. Bell A, Bell D, Weber RS, et al: CpG Island Methylation Profiling in Human
Salivary Gland Adenoid Cystic Carcinoma. Cancer 2011, 117:2898–2909.
30. Uhm KO, Lee ES, Lee YM, et al: Aberrant promoter CpG islands
methylation of tumor suppressor genes in cholangiocarcinoma. Oncol
Res 2008, 17:151–157.
31. Wu X, Liu W, Tian Y, et al: Aberrant methylation of death-associated
protein kinase 1 CpG islands in myelodysplastic syndromes. Acta
Haematol 2011, 125:179–185.
32. Li W, Li X, Wang W, et al: NOR1 is an HSF1- and NRF1-regulated putative
tumor suppressor inactivated by promoter hypermethylation in
nasopharyngeal carcinoma. Carcinogenesis 2011, 32:1305–1314.
33. Du C, Huang T, Sun D, et al: CDH4 as a novel putative tumor suppressor
gene epigenetically silenced by promoter hypermethylation in
nasopharyngeal carcinoma. Cancer Lett 2011, 309:54–61.
34. Hervouet E, Vallette FM, Cartron PF: Dnmt3/transcription factor
interactions as crucial players in targeted DNA methylation. Epigenetics
2009, 4:487–499.
35. Weng W, Yang Q, Huang M, et al: c-Myc inhibits TP53INP1 expression via
promoter methylation in esophageal carcinoma. Biochem Biophys Res
Commun 2011, 405:278–284.
36. Licchesi JD, Van Neste L, Tiwari VK, et al: Transcriptional regulation of Wnt
inhibitory factor-1 by Miz-1/c-Myc. Oncogene 2010, 29:5923–5934.
37. Calmon MF, Rodrigues RV, Kaneto CM, et al: Epigenetic silencing of
CRABP2 and MX1 in head and neck tumors. Neoplasia 2009, 11:1329–1339.
38. Brieger J, Mann SA, Pongsapich W, et al: Pharmacological genome
demethylation increases radiosensitivity of head and neck squamous
carcinoma cells. Int J Mol Med 2012, 29:505–509.
39. Bauman J, Verschraegen C, Belinsky S, et al: A phase I study of
5-azacytidine and erlotinib in advanced solid tumor malignancies.
Cancer Chemother Pharmacol 2012, 69(2):547–54.
doi:10.1186/1471-2407-12-219
Cite this article as: Yang et al.: Promoter hypermethylation-induced
transcriptional down-regulation of the gene MYCT1 in laryngeal
squamous cell carcinoma. BMC Cancer 2012 12:219.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
